Table II.
Prognostic subgroups derived from survival tree analysis in patients with newly diagnosed Ewing sarcoma
| Group | Prognostic Variables | SEER 5 yr % OS (95% CI) |
COG 5 yr % OS (95% CI) |
COG 5 yr % EFS (95% CI) |
COG I/E 5 yr % OS (95% CI) |
|---|---|---|---|---|---|
| 1 | Localized; Age < 18; Non-pelvic |
79 (74 – 82) N = 601 |
79 (76 – 81) N = 1,041 |
72 (69 – 75) N = 1,041 |
81 (78 – 83) N = 921 |
| 2 | Localized; Age < 18; Pelvic primary |
64 (60 – 69) N = 572 |
64 (59 – 69) N = 373 |
57 (52 – 62) N = 373 |
68 (62 – 72) N = 317 |
| Localized; Age ≥ 18; White, non-Hispanic | |||||
| 3 | Localized; Age ≥ 18; Other Races |
49 (40 – 57) N = 180 |
53 (27 – 74) N = 22 |
47 (24 – 68) N = 22 |
53 (27 – 74) N = 20 |
| 4 | Metastatic; Age < 18 |
39 (33 – 45) N = 273 |
38 (30 – 45) N = 198 |
25 (19 – 32) N = 198 |
40 (31 – 49) N = 147 |
| 5 | Metastatic; Age ≥ 18 |
21 (16 – 26) N = 319 |
21 (8 – 37) N = 46 |
13 (5 – 26) N = 46 |
16 (4 – 36) N = 36 |
Abbreviations: SEER Surveillance Epidemiology and End Results; COG Children's Oncology Group; yr year; CI confidence interval; I/E ifosfamide and etoposide received as part of chemotherapy; N = number of participants in that group; OS overall survival; EFS event-free survival